Steen Klysner, Ph.D. and CEO

new-sk

Dr. Klysner graduated in Biochemistry from the University of Copenhagen and subsequently received a doctoral degree in combination with an industrial research degree from the Technical University of Denmark and the Danish Academy of Technical Sciences, respectively.

Dr. Klysner has more than 30 years of experience from the Biotech- and Biopharmaceutical industry, from several executive and non-executive positions at ALK-Abello, Novo Nordisk, Pharmexa, Nordic Vaccine, and most recently as SVP of preclinical R&D at Allergopharma, the Allergy business unit of Merck KGaA in Germany. He has a solid track record within management, strategy, financing and partnering, primarily focused within the development of novel immune therapy and vaccine products.

He became CEO of ExpreS2ion Biotechnologies ApS and ExpreS2ion Biotech Holding AB in 2016 and later Chairman of the Board of AdaptVac ApS in 2017.

Dr. Klysner is married to Dr. Charlotte Dyring, co-founder of ExpreS2ion Biotechnologies ApS

Warrants:        42,043

 

Charlotte Dyring, MSc PhD, COO and co-founder

new-cd

Dr.

Dyring graduated in Chemical Engineering from the Technical University of Denmark and subsequently received a doctoral degree in combination with an Nordic industrial research degree from the Technical University of Denmark and the Danish Academy of Technical Sciences, respectively.

Dr. Dyring has more than 25 years of experience working in several scientific and managerial positions in the pharmaceutical and the biotechnology industry at Kabi Pharmacia (later Pharmacia & Upjohn) and Pharmexa A/S (Affitech A/S). She has an extensive track record in the field of protein expression in animal cells, mastering a wide range of expression systems, tools and techniques. She has substantial experience with upstream process development according to industry standards, including the process transfer to cGMP manufacturing. Dr. Dyring is a recognised world leading expert of the Drosophila S2 expression technology and was instrumental in the development of the ExpreS2 technology to the current level of sophistication and robustness.

Dr. Dyring is a co-founder of ExpreS2ion Biotechnologies ApS and CEO of the Company from founding to April 2016.

She is married to the present CEO of ExpreS2ion Biotech holding AB, Dr. Steen Klysner.

Shares:           Dr. Dyring owns 39.23 % of the founder owned company ExpreS2ion Holding ApS,  which controls 1,744,370 (12.82%) of the shares in ExpreS2ion Biotech Holding AB.

Warrants:       32,700

 

Wian de Jongh, MSc PhD, CSO and co-founder
new-wdjDr. de Jongh has a MSc (cum laude) in Chemical Engineering from the University of Stellenbosch, South Africa and a doctorate in Biotechnology from the Technical University of Denmark. He was furthermore awarded an affiliated associate professorship at DTU in 2017.

Dr. de Jongh is an expert within advanced cell line genetic engineering and applied metabolic engineering targeting improved production characteristics. Dr. de Jongh has significant experience from the pharmaceutical industry within molecular biology, cell line development, project management, upstream process development, process scale-up, regulatory systems and transfer to cGMP manufacturing.

Dr. de Jongh was instrumental in the development of the ExpreS2 technology. He has served on the steering committee and as project manager on several larger grant-funded projects. Dr. de Jongh is employed since 2011. In addition, he is the acting CEO and board member of AdaptVac ApS since 2017.

Dr. de Jongh is co-founder of ExpreS2ion Biotechnologies ApS

Shares:           Dr. de Jongh owns 32.22% of the founder owned company ExpreS2ion Holding ApS,  which owns 1,744,370 (12.82%) of the shares in ExpreS2ion Biotech Holding AB.

Warrants:        32,700

 

Bent U. Frandsen, MSc, VP Business Development

new-buf

Bent Frandsen holds a MSc in Finance and Strategic Planning from Copenhagen Business School, Denmark. He has more than 25 years of professional experience in management, finance, and business development positions in multinational companies, including more than 20 years life science experience at public listed companies: Lundbeck, ALK-Abelló, Coloplast, and private companies: NsGene, CMC Biologics, and Amphidex.

He is experienced in licensing, services, M&A, and new cash deals in excess of €200 million, and has furthermore been in charge of successfully closing numerous collaboration agreements pertaining to research and development of both new chemical entities and biologicals.

Bent Frandsen is employed since 2016 and entered the board of AdaptVac ApS in 2017.

Shares:           20,223

Warrants:       32,700